Research Article
Variation of PPARG Expression in Chemotherapy-Sensitive Patients of Hypopharyngeal Squamous Cell Carcinoma
Table 2
Clinical data of HSCC patients for GSE85607.
| Subject ID | Gender | Age | TNM stage | Histologic differentiation degree | Chemotherapy response |
| S1 | Female | 71 | T2N0M0 | Poorly differentiated | PR | S2 | Male | 68 | T2N0M0 | Well differentiated | PR | S3 | Male | 55 | T4aN0M0 | Well differentiated | PR | S4 | Male | 68 | T3N0M1 | Moderately differentiated | PR | S5 | Male | 58 | T3N0M0 | Well differentiated | PR | S6 | Male | 52 | T2N0M0 | Well differentiated | PR | S7 | Male | 56 | T2N0M0 | Well differentiated | PR | N1 | Male | 58 | T4aN3M0 | Poorly differentiated | SD | N2 | Male | 61 | T3N2M0 | Poorly differentiated | SD | N3 | Male | 56 | T1N0M0 | Well differentiated | SD | N4 | Male | 59 | T3N2M0 | Moderately differentiated | PD |
|
|
Note: CR (complete response): disappearance; confirmed at 4 weeks; PR (partial response): 50% decrease; confirmed at 4 weeks; SD (stable disease): neither PR nor PD criteria are met; PD (progressive disease): 25% increase; no CR, PR, or SD documented before a progressed disease.
|